OKYO Pharma Limited Ordinary Shares (OKYO)
Stock · NASDAQ · Health Care
$1.41as of 10/16/2026
Price chart
Active signals
OKYO Signal Track Record
How signals performed across all stocks →What OKYO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -3.4% | 45% | September 21, 2026 |
| Bollinger Band Breakout | 21 | -8.3% | 29% | October 9, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -2.8% | 46% | January 28, 2026 |
| Bollinger Band Breakdown | 12 | +4.8% | 67% | September 11, 2026 |
| Any 20-session window (baseline) | -1.0% | 47% |
Computed by MarketWall from daily closing prices since March 3, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OKYO
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 5
- Website
- okyopharma.com/
Fundamentals
- 1-day range
- $1.4$1.46
- Market cap
- $51.94M
- P/E (trailing)
- —
- P/E (forward)
- -2.17
- EPS (trailing)
- $-0.24
- Dividend yield
- —
- Beta
- 0.09
- Avg. volume
- 81.4K
Forecasts
3 analyst ratings
OKYO Pharma Limited Ordinary Shares Competitors
Chosen by industry and closest market cap.
- OKYOOKYO Pharma Limited Ordinary Shares$1.41▼ 1.40%Market cap $51.94MP/E —$1.26$3.2
- INMBINmune Bio Inc. Common stock$1.57▼ 4.85%Market cap $50.78MP/E —$1.09$2.6
- TCRXTScan Therapeutics Inc. Common Stock$0.231▼ 3.35%Market cap $49.88MP/E —$0.2243$2.57
- TILInstil Bio Inc. Common Stock$5.91▼ 3.59%Market cap $49.37MP/E —$5.67$21.64
- ATYRaTyr Pharma Inc. Common Stock$0.174▼ 5.43%Market cap $49.22MP/E —$0.2$1.11
- INKTMiNK Therapeutics Inc. Common Stock$9.41▼ 5.33%Market cap $54.80MP/E —$8.48$16.93
- EXOZeXoZymes Inc. Common Stock$4.09▲ 2.25%Market cap $47.57MP/E —$4.35$18.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OKYO OKYO Pharma Limited Ordinary Shares | $51.94M | — | $1.41 | ▼ 1.40% | $1.26$3.2 |
| INMB INmune Bio Inc. Common stock | $50.78M | — | $1.57 | ▼ 4.85% | $1.09$2.6 |
| TCRX TScan Therapeutics Inc. Common Stock | $49.88M | — | $0.231 | ▼ 3.35% | $0.2243$2.57 |
| TIL Instil Bio Inc. Common Stock | $49.37M | — | $5.91 | ▼ 3.59% | $5.67$21.64 |
| ATYR aTyr Pharma Inc. Common Stock | $49.22M | — | $0.174 | ▼ 5.43% | $0.2$1.11 |
| INKT MiNK Therapeutics Inc. Common Stock | $54.80M | — | $9.41 | ▼ 5.33% | $8.48$16.93 |
| EXOZ eXoZymes Inc. Common Stock | $47.57M | — | $4.09 | ▲ 2.25% | $4.35$18.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal PainYahoo · 10/6/2026
- OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drugYahoo · 10/6/2026
- OKYO Pharma Announces First Patients Enrolled In Phase 3 NEPTUNE Trial Of Urcosimod For Neuropathic Corneal Painbenzinga · 10/6/2026
- OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal PainYahoo · 10/6/2026
- OKYO Pharma Announces First Patients Enrolled In Phase 3 NEPTUNE Trial Of Urcosimod For Neuropathic Corneal PainBenzinga · 10/6/2026
- OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific ConferencesYahoo · 9/29/2026
Insider Activity
Insider Actions →- Rajkumar Patil V · July 27, 2026 · Grant3.4K @ $1.49
- Rajkumar Patil V · July 27, 2026 · Buy3.4K @ $1.49
- Robert John Dempsey · July 22, 2026 · Buy15.0K @ $1.54
- Robert John Dempsey · July 22, 2026 · Grant15.0K @ $1.54
- Flavio Mantelli · July 21, 2026 · Buy20.0K @ $1.4
- John P. Brancaccio · July 21, 2026 · Buy5.0K @ $1.48
- Gary S. Jacob · July 21, 2026 · Buy3.5K @ $1.4
- Gabriele M. Cerrone · July 21, 2026 · Buy22.5K @ $1.45
- John P. Brancaccio · July 21, 2026 · Grant5.0K @ $1.48
- Gary S. Jacob · July 21, 2026 · Grant3.5K @ $1.4
- Gabriele M. Cerrone · July 21, 2026 · Grant22.5K @ $1.45
- Flavio Mantelli · July 21, 2026 · Grant20.0K @ $1.4
- Gabriele M. Cerrone · July 20, 2026 · Buy25.0K @ $1.4
- Gabriele M. Cerrone · July 20, 2026 · Grant25.0K @ $1.4
- Shah Keeren Rameshchandra · June 8, 2026 · Grant40.0K @ $1.85
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
OKYO Pharma to Present at Ophthalmic Scientific Conferences
OKYO Pharma announced it will present and participate in several upcoming ophthalmic scientific conferences. The company’s involvement highlights its focus on eye‑care products and may increase visibility among researchers and clinicians. This activity could support interest in OKYO’s pipeline as the firm seeks to advance its ophthalmic therapies.
OKYO Pharma to Present at Ophthalmic Scientific Conferences. OKYO Pharma announced it will present and participate in several upcoming ophthalmic scientific conferences. The company’s involvement highlights its focus on eye‑care products and may increase visibility among researchers and clinicians. This activity could support interest in OKYO’s pipeline as the firm seeks to advance its ophthalmic therapies.